Venlafaxine — $0 on Listed Strengths

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Anxiety Disorder

• Alprazolam
• Buspirone
• Duloxetine
• Escitalopram
• Lorazepam
• Paroxetine
• Sertraline

Also listed for Generalized Anxiety Disorder

• Gabapentin

Other medications in Mental Health

• Vilazodone
• Vortioxetine
• Zaleplon
• Ziprasidone
• Zuranolone
• Acamprosate
• Amphetamine Salts
• Aripiprazole

About Venlafaxine

Venlafaxine, commonly known by its brand name Effexor XR, is a widely prescribed medication that plays a crucial role in managing various mental health conditions. It’s an effective tool for many, but prescription costs can be a barrier. TheDrugClub is dedicated to making essential medications like venlafaxine accessible and affordable, helping you save significantly.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Venlafaxine is approved for (FDA label)

Venlafaxine tablets are indicated for the treatment of major depressive disorder. The efficacy of venlafaxine tablets in the treatment of major depressive disorder was established in 6-week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III or DSM-III-R category of major depression and in a 4-week controlled trial of inpatients meeting diagnostic criteria for major depression with melancholia (see CLINICAL TRIALS ).

Source: Read the full FDA label on DailyMed. Label effective date: August 28, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Venlafaxine (FDA label)

Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of Major Depressive Disorder (MDD) and other psychiatric disorders. Anyone considering the use of venlafaxine tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Venlafaxine tablets are not approved for use in pediatric patients. (See WARNINGS : Clinical Worsening and Suicide Risk, PRECAUTIONS: Information for Patients , and PRECAUTIONS: Pediatric Use )

Source: FDA prescribing information (DailyMed). Set ID: e14bfb9f-3bd2-4419-9294-9c286e79730a. SPL document ID: 5a1cbb31-bb41-0924-e063-6294a90a6b04. Label effective date: August 28, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Venlafaxine (FDA label)

Associated with Discontinuation of Treatment Nineteen percent (537/2897) of venlafaxine patients in Phase 2 and Phase 3 depression studies discontinued treatment due to an adverse event.

Source: FDA prescribing information (DailyMed). Set ID: e14bfb9f-3bd2-4419-9294-9c286e79730a. SPL document ID: 5a1cbb31-bb41-0924-e063-6294a90a6b04. Label effective date: August 28, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Venlafaxine (FDA label)

Hypersensitivity to venlafaxine hydrochloride or to any excipients in the formulation. The use of MAOIs intended to treat psychiatric disorders with venlafaxine tablets or within 7 days of stopping treatment with venlafaxine tablets is contraindicated because of an increased risk of serotonin syndrome. The use of venlafaxine tabletswithin 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated (see WARNINGS and DOSAGE AND ADMINISTRATION ). Starting venlafaxine tablets in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see WARNINGS and DOSAGE AND ADMINISTRATION ).

Source: FDA prescribing information (DailyMed). Set ID: e14bfb9f-3bd2-4419-9294-9c286e79730a. SPL document ID: 5a1cbb31-bb41-0924-e063-6294a90a6b04. Label effective date: August 28, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Venlafaxine (FDA label)

As with all drugs, the potential for interaction by a variety of mechanisms is a possibility. Alcohol A single dose of ethanol (0.5 g/kg) had no effect on the pharmacokinetics of venlafaxine or ODV when venlafaxine was administered at 150 mg/day in 15 healthy male subjects. Additionally, administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine. Cimetidine Concomitant administration of cimetidine and venlafaxine in a steady-state study for both drugs resulted in inhibition of first-pass metabolism of venlafaxine in 18 healthy subjects.

Source: FDA prescribing information (DailyMed). Set ID: e14bfb9f-3bd2-4419-9294-9c286e79730a. SPL document ID: 5a1cbb31-bb41-0924-e063-6294a90a6b04. Label effective date: August 28, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.